Bristol-Myers Squibb (NYSE:BMY) Stock Position Raised by XTX Topco Ltd

XTX Topco Ltd lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 400.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,465 shares of the biopharmaceutical company's stock after acquiring an additional 73,183 shares during the period. Bristol-Myers Squibb comprises approximately 0.3% of XTX Topco Ltd's holdings, making the stock its 23rd largest holding. XTX Topco Ltd's holdings in Bristol-Myers Squibb were worth $3,799,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. ESL Trust Services LLC bought a new position in shares of Bristol-Myers Squibb in the 1st quarter worth about $27,000. LGT Financial Advisors LLC lifted its holdings in Bristol-Myers Squibb by 42.7% in the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 227 shares during the last quarter. MFA Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb in the second quarter valued at approximately $39,000. Fairman Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $42,000. Finally, Beach Investment Counsel Inc. PA acquired a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $42,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BMY. Jefferies Financial Group boosted their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a "hold" rating in a research report on Wednesday, August 28th. Barclays boosted their price target on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an "underweight" rating in a report on Thursday, August 22nd. TD Cowen increased their price objective on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a "hold" rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a "hold" rating for the company in a research note on Tuesday, July 23rd. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research note on Monday. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has a consensus rating of "Hold" and an average target price of $55.00.

Bristol-Myers Squibb Price Performance

BMY stock traded down $0.73 during trading hours on Thursday, hitting $49.02. 8,840,271 shares of the stock traded hands, compared to its average volume of 14,976,102. The stock has a 50-day simple moving average of $47.50 and a 200 day simple moving average of $46.50. The company has a market cap of $99.36 billion, a P/E ratio of -15.81, a P/E/G ratio of 12.59 and a beta of 0.46. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $59.46. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company had revenue of $12.20 billion for the quarter, compared to analysts' expectations of $11.54 billion. During the same quarter in the previous year, the company posted $1.75 EPS. The business's revenue was up 8.7% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.90%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.